Skip to main content
. 2022 Nov 11;12:19294. doi: 10.1038/s41598-022-23841-2

Table 2.

Major changes obtained in haematology and coagulation measurements (group mean values ± standard deviation) in male and female rats treated intravenously for 4 weeks and 2 weeks of recovery period with 0 (vehicle = 0.9% saline solution), 5, 9 and 15 mg/kg/day of SET-M33 peptide.

Sex Dose (mg/kg/day) Haematology and coagulation week 4 of treatment—Group mean values
Hct (L/L) Hb (g/dL) RBC (× 1012/L) Retic (× 1012/L) Retic (%) MCH (pg) MCHC (g/dL) MCV (fL) WBC (× 109/L) HDW (g/dL) L (× 109/L) LUC (× 109/L) Plt (× 109/L) SPT (sec) SAPT (sec)
Male 0 0.454 ± 0.0145 15.3 ± 0.45 8.49 ± 0.32 0.139 ± 0.0233 1.64 ± 0.253 18.00 ± 0.49 33.70 ± 0.71 53.50 ± 0.79 10.00 ± 1.761 2.94 ± 0.097 8.67 ± 1.283 0.08 ± 0.022 779 ± 143.1 23.0 ± 6.54 37.6 ± 5.65
5 0.401** ± 0.0198 13.5** ± 0.48 7.55** ± 0.306 0.152 ± 0.0283 2.00* ± 0.352 17.90 ± 0.38 33.80 ± 0.76 53.00 ± 1.15 10.76 ± 1.713 3.21** ± 0.126 9.73 ± 1.418 0.08 ± 0.027 917* ± 95.4 21.8 ± 0.82 36.5 ± 6.18
9 0.348** ± 0.0275 11.9** ± 0.84 6.81** ± 0.538 0.076** ± 0.0292 1.10** ± 0.357 17.40* ± 0.39 34.20 ± 0.73 51.0** ± 1.71 11.36 ± 2.206 3.30** ± 0.174 10.30 ± 2.104 0.10 ± 0.049 923* ± 148.7 24.1** ± 0.68 31.6* ± 5.31
15 0.311** ± 0.0158 10.7** ± 0.58 6.15** ± 0.322 0.037** ± 0.0091 0.60** ± 0.160 17.50* ± 0.47 34.6** ± 0.50 50.50** ± 0.77 13.51** ± 2.506 3.23** ± 0.151 12.35** ± 2.216 0.14** ± 0.053 961** ± 130.1 24.5** ± 1.05 31.9* ± 5.11
Female 0 0.416 ± 0.0133 14.1 ± 0.47 7.62 ± 0.23 0.176 ± 0.0445 2.31 ± 0.52 18.50 ± 0.40 33.80 ± 0.73 54.70 ± 1.64 7.30 ± 2.064 2.76 ± 0.096 6.25 ± 2.013 0.05 ± 0.023 853 ± 204.900 21.9 ± 1.150 37.0 ± 5.260
5 0.382** ± 0.0127 12.9** ± 0.46 7.11** ± 0.291 0.180 ± 0.0473 2.55 ± 0.712 18.20 ± 0.40 33.90 ± 0.43 53.70 ± 0.91 7.11 ± 0.596 2.92 ± 0.127 6.31 ± 0.710 0.05 ± 0.011 1004* ± 115.600 21.9 ± 0.660 33.1 ± 5.900
9 0.352** ± 0.0199 12.0** ± 0.48 6.61** ± 0.358 0.112** ± 0.0462 1.69* ± 0.646 18.10 ± 0.43 34.00 ± 0.80 53.30* ± 0.76 9.15 ± 2.982 3.34** ± 0.189 7.91 ± 2.475 0.08** ± 0.038 1075** ± 136.70 23.6** ± 1.00 26.7** ± 3.890
15 0.284** ± 0.0223 9.7** ± 0.75 5.44** ± 0.488 0.060** ± 0.0162 1.12** ± 0.345 17.9** ± 0.48 34.20 ± 0.33 52.3** ± 1.44 10.34** ± 1.917 2.99** ± 0.199 9.22** ± 1.713 0.09** ± 0.019 1250** ± 181.00 23.3** ± 1.270 25.6** ± 5.910
Sex Dose (mg/kg/day) Haematology and coagulation week 2 of recovery—Group mean values
Hct (L/L) Hb (g/dL) RBC (× 1012/L) Retic (× 1012/L) Retic (%) MCH (pg) MCHC (g/dL) MCV (fL) WBC (× 109/L) HDW (g/dL) L (× 109/L) LUC (× 109/L) Plt (× 109/L) SPT (sec) SAPT (sec)
Male 0 0.450 ± 0.0136 15.2 ± 0.4 8.73 ± 0.359 0.122 ± 0.0091 1.40 ± 0.13 17.4 ± 0.61 33.8 ± 0.74 51.6 ± 0.8 9.86 ± 1.818 3.03 ± 0.075 8.39 ± 1.371 0.08 ± 0.026 722 ± 58.2 21.5 ± 0.63 20.3 ± 3.44
15 0.262** ± 0.0197 9.5** ± 0.55 5.36** ± 0.37 0.061* ± 0.412 1.1 ± 0.797 17.7 ± 0.47 36.1** ± 0.98 49.0 ± 2.37 6.84* ± 1.913 3.25* ± 0.16 6.12 ± 1.655 0.05 ± 0.034 919* ± 169.1 21.1 ± 0.67

13.3*

 ± 3.41

Female 0 0.431 ± 0.0097 15 ± 0.29 8.04 ± 0.097 0.083 ± 0.0311 1.03 ± 0.385 18.7 ± 0.29 34.9 ± 0.31 53.6 ± 1.07 7.47 ± 1.792 2.64 ± 0.102 6.16 ± 1.375 0.06 ± 0.014 81 ± 135 22.4 ± 0.33 20.4 ± 1.8
15 0.268** ± 0.0087 9.3** ± 0.34 5.31** ± 0.139 0.063 ± 0.0254 1.17 ± 0.458 17.5** ± 0.62 34.7 ± 0.5 50.6** ± 1.15 7.89 ± 1.712 3.04** ± 0.167 6.58 ± 1.708 0.05 ± 0.018 1208** ± 106.8 22.9 ± 0.79 16.8* ± 1.37

Hct haematocrit, Hb haemoglobin, RBC erythrocyte count, Retic reticulocyte count (absolute and relative), MCH mean corpuscular haemoglobin, MCHC mean corpuscular haemoglobin concentration, MCV mean corpuscular volume, WBC leukocyte count, total, HDW haemoglobin concentration distribution width, L lymphocytes, LUC large unstained cells, Plt platelet (thrombocyte) count, SPT prothrombin time, SAPT activated partial thromboplastin time.

Significant differences between peptide vs. control groups were expressed at the 5% (*p < 0.05) or 1% (**p < 0.01) level. For statistical analysis, Dunnett, Shirley’ Williams, Wilcoxon and t tests were used.